Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Momenta Pharma (MNTA)

Momenta Pharma (MNTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Momenta Pharmaceuticals Announces Poster Presentation at the 61st American Society of Hematology Annual Meeting and Exposition

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that Santiago Arroyo, M.D., Ph.D., Chief Medical Officer, will deliver a poster presentation at the upcoming 61 American Society of Hematology...

MNTA : 16.10 (-1.89%)
Myriad Genetics has the Best Relative Performance in the Biotechnology Industry (MYGN , MNTA , BPMC , ICPT , TGTX )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

BPMC : 71.76 (-2.05%)
MNTA : 16.10 (-1.89%)
MYGN : 24.42 (+3.30%)
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will...

MNTA : 16.10 (-1.89%)
Momenta Pharmaceuticals (MNTA) Reports Q3 Loss, Tops Revenue Estimates

Momenta (MNTA) delivered earnings and revenue surprises of -14.29% and 39.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

MNTA : 16.10 (-1.89%)
Momenta: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Thursday reported a loss of $44.5 million in its third quarter.

MNTA : 16.10 (-1.89%)
Momenta Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today reported its financial...

MNTA : 16.10 (-1.89%)
Hospitals, Third-Party Payors, and People Who Bought or Provided Reimbursement for the Anticoagulant Medications Lovenox® or Generic Enoxaparin, Could Be Included in a Class Action Lawsuit

The following is being released by Lieff Cabraser Heimann & Bernstein, LLP.

MNTA : 16.10 (-1.89%)
Momenta Pharmaceuticals Announces Date of Third Quarter 2019 Financial Results Conference Call and Webcast

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will...

MNTA : 16.10 (-1.89%)
Momenta Pharmace Shares Up 20.6% Since SmarTrend's Buy Recommendation (MNTA)

SmarTrend identified an Uptrend for Momenta Pharmace (NASDAQ:MNTA) on July 31st, 2019 at $11.41. In approximately 2 months, Momenta Pharmace has returned 20.60% as of today's recent price of $13.76.

MNTA : 16.10 (-1.89%)
Spectrum Pharmac is Among the Companies in the Biotechnology Industry with the Best Relative Performance (SPPI , VNDA , MNTA , ESPR , CHRS )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

MNTA : 16.10 (-1.89%)
SPPI : 8.88 (+3.02%)
VNDA : 15.11 (+2.51%)
Watch for Momenta Pharmace to Potentially Pullback After Gaining 5.19% Yesterday

Momenta Pharmace (NASDAQ:MNTA) traded in a range yesterday that spanned from a low of $13.32 to a high of $13.84. Yesterday, the shares gained 5.2%, which took the trading range above the 3-day high...

MNTA : 16.10 (-1.89%)
Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the appointment...

MNTA : 16.10 (-1.89%)
Momenta Pharmace Shares Up 18.1% Since SmarTrend's Buy Recommendation (MNTA)

SmarTrend identified an Uptrend for Momenta Pharmace (NASDAQ:MNTA) on July 31st, 2019 at $11.41. In approximately 2 months, Momenta Pharmace has returned 18.05% as of today's recent price of $13.47.

MNTA : 16.10 (-1.89%)
Momenta (MNTA) Up 10% Since Last Earnings Report: Can It Continue?

Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MNTA : 16.10 (-1.89%)
Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss

Momenta (MNTA) reports a wider loss and misses on sales in Q2 .

ABBV : 85.32 (+0.13%)
MNTA : 16.10 (-1.89%)
REGN : 340.35 (-0.42%)
MYL : 17.16 (-2.56%)
Momenta Pharmaceuticals (MNTA) Reports Q2 Loss, Misses Revenue Estimates

Momenta (MNTA) delivered earnings and revenue surprises of -176.19% and -43.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

MNTA : 16.10 (-1.89%)
Momenta: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Friday reported a loss of $114 million in its second quarter.

MNTA : 16.10 (-1.89%)
Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results

-- Launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), the Company's third study of its FcRn inhibitor; top-line data expected by end of 2021 --

MNTA : 16.10 (-1.89%)
Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, announced the launch of an...

MNTA : 16.10 (-1.89%)
Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that the...

MNTA : 16.10 (-1.89%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.77 , AIZ -1.40 , SBAC +1.52 , SO -0.70 , WELL +0.26
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar